4//SEC Filing
GOLDSTEIN DOV A MD 4
Accession 0001120478-26-000003
CIK 0001709941other
Filed
Jan 14, 7:00 PM ET
Accepted
Jan 15, 4:22 PM ET
Size
14.8 KB
Accession
0001120478-26-000003
Insider Transaction Report
Form 4
GOLDSTEIN DOV A MD
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
[F1]2026-01-13$8.39/sh+27,000$226,530→ 49,408 total - Sale
Common Stock
[F1][F2]2026-01-13$18.43/sh−8,974$165,371→ 40,434 total - Sale
Common Stock
[F1][F3]2026-01-13$19.45/sh−4,440$86,370→ 35,994 total - Sale
Common Stock
[F1][F4]2026-01-13$20.54/sh−11,663$239,549→ 24,331 total - Sale
Common Stock
[F1][F5]2026-01-13$21.08/sh−1,923$40,538→ 22,408 total - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F6]2026-01-13−27,000→ 92,587 totalExercise: $8.39Exp: 2034-04-16→ Common Stock (27,000 underlying)
Footnotes (6)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2024.
- [F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.91 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 5 of this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.00 to $19.86 per share, inclusive.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.04 to $21.02 per share, inclusive.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.04 to $21.15 per share, inclusive.
- [F6]The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on May 17, 2024, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Additionally, the entire award is exercisable at any time pursuant to an early exercise feature of the option award.
Signature
/s/ Dov A. Goldstein|2026-01-15
Documents
Issuer
BioAge Labs, Inc.
CIK 0001709941
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001120478
Filing Metadata
- Form type
- 4
- Filed
- Jan 14, 7:00 PM ET
- Accepted
- Jan 15, 4:22 PM ET
- Size
- 14.8 KB